Submitted Successfully!
To reward your contribution, here is a gift for you: A free trial for our video production service.
Thank you for your contribution! You can also upload a video entry or images related to this topic.
Version Summary Created by Modification Content Size Created at Operation
1
Sara Álvaro Sánchez
 + 1126 word(s) 1126 2021-12-14 04:56:28 |
2 update references and layout
Amina Yu
-32 word(s) 1094 2022-01-20 02:50:21 | |
3 update EC
Amina Yu
Meta information modification 1094 2022-01-21 09:21:37 | |
4 update EC
Amina Yu
Meta information modification 1094 2022-01-24 04:14:30 |

Video Upload Options

Do you have a full video?
Send video materials Upload full video

Confirm

Are you sure to Delete?
Yes No
Cite
If you have any further questions, please contact Encyclopedia Editorial Office.
Álvaro Sánchez, S. Genetic Counselling for Rare Diseases in Spain. Encyclopedia. Available online: https://encyclopedia.pub/entry/18518 (accessed on 31 July 2024).
Álvaro Sánchez S. Genetic Counselling for Rare Diseases in Spain. Encyclopedia. Available at: https://encyclopedia.pub/entry/18518. Accessed July 31, 2024.
Álvaro Sánchez, Sara. "Genetic Counselling for Rare Diseases in Spain" Encyclopedia, https://encyclopedia.pub/entry/18518 (accessed July 31, 2024).
Álvaro Sánchez, S. (2022, January 19). Genetic Counselling for Rare Diseases in Spain. In Encyclopedia. https://encyclopedia.pub/entry/18518
Álvaro Sánchez, Sara. "Genetic Counselling for Rare Diseases in Spain." Encyclopedia. Web. 19 January, 2022.
Genetic Counselling for Rare Diseases in Spain
Edit
This entry is adapted from the peer-reviewed paper 10.3390/diagnostics11122320

Genetic Counseling is essential for providing personalized information and support to patients with Rare Diseases (RD). Unlike most other developed countries, Spain does not recognize geneticists or genetic counsellors as healthcare professionals. Thus, patients with RD face not only challenges associated with their own disease but also deal with lack of knowledge, uncertainty, and other psychosocial issues arising as a consequence of diagnostic delay.

genetic counselling rare diseases professional recognition

1. The Role of Genetic Counselling for Rare Diseases

Rare Diseases (RD) are defined as such by their low prevalence although their frequency changes depending on the continent; for instance, the European definition is that affecting less than 1/2000 individuals. It is mainly their uncommonness that makes RD so difficult to diagnose producing a diagnostic delay of more than 5 years [1]. 

The role of a genetic counsellor involves many tasks (core competencies) that are expected to accomplish in order to ensure an individual has enough personalized information and support to be able to deal not only with their genetic disease as well as to make informed decisions[2][3][4]. Diagnosis of RD is not the end of the journey but rather the beginning. Once a genetic diagnosis is achieved, patients need support to understand not only the implications of this verdict and the real meaning of carrying a genetic abnormality but also, and sometimes more importantly, to grief and to adapt to all psychosocial aspects involved[5][6][7]. Therefore, from the very first visit to a specialist, patients should receive support from a genetic counsellor (in coordination with multidisciplinary genetics units). Furthermore, genetics is shared among the family having implications for the closer relatives accounting for their risk of carrying a disease-causing variant [8]. Inheritance of these variants increases the risk of passing the disease to the next generation, and thus, some relatives who might be carriers will need support, help and guidance to manage and plan a future pregnancy trying to reduce risks of having an affected child[9][10] .

It is worth mentioning at this point some studies. First, one evaluating the economic impact of using genomic sequencing to diagnose RD, that highlighted that parents find genetic counsellors a valuable resource facilitating complex decisions [11]. Some others highlight the cost-effectiveness of providing Genetic Counselling [12][13] and finally several studies show the harm produced when no appropriate Genetic Counselling is provided to RD patients, impacting at many levels[14]. For example, living in a different region than the patient testing positive might make family screening of relatives difficult and unequal access to genetics services will also complicate cascade testing[7][8][15] .

2. Genetic Services (Including Genetic Counselling) for Rare Diseases in Spain

Genetic services in Spain are provided by professionals who are not usually specifically trained in that field, what impacts negatively in the management of patients with RD and their families. Oncology and Reproductive Medicine (including prenatal screening and neonatal care) are two clinical areas historically related to Genetic Counselling, but this is not the case for RD. These two facts, that complicate patient access to Genetic Counselling Services, are due in part to the lack of recognition of Clinical Genetics as a healthcare specialty.

In contrast with the lack of specific Genetic Counselling Services for RD in Spain, highly specialized multidisciplinary units and/or centres (CSUR, Reference Centres, Services and Units) for specific diseases (some of them of low prevalence) are being created since 2008. One of the main objectives of these units is not necessarily medical assistance but to become a reference contact for disease management strategies definition as well as support for both, patients and clinicians dealing with a particular disease [16]. These centres are not a genetic service itself, but they agglutinate multidisciplinary groups of clinical specialists in which genetic counsellors are not usually incorporated.

Contrarily to the difficulties encountered for the recognition of the profession, Spain has made a significant effort to improve RD management; in fact, collaborations between research centres and hospitals have been created for neuromuscular[17][18] , retinal[19][20]  and cardiovascular[21] rare diseases, although this effort should be extended to, ideally, all RD.

3. Current Needs and Future Directions of Genetic Counselling for Rare Diseases

The so-called “diagnostic odyssey” is the process during which most patients with a rare disease and their families try to find the cause, name, prognostic and treatment of their disease[15][22] . The future of RD envisions a faster diagnosis thanks to high-throughput Next Generation Sequencing (NGS) technologies as well as artificial intelligence [23] with the intention of helping clinicians to shorten the time to diagnosis. However, it is important to recognise diagnostic limitations for each technology; and it is at this point at which genetic (or genomic) counsellors provide an added value. Furthermore, the fact that some patients have multiple disease-causing variants (polygenic diseases) and also several genetic diagnoses complicates interpretation of genetic data, thus, requiring expert geneticists (all three specialties: clinical geneticists, genetic counsellors and clinical laboratory geneticists) to provide enough information and support to patients[24][25] .

Shortening the diagnostic process and providing adequate management to patients with a rare disease in Spain necessarily implies a series of changes both in the Spanish National Health System (SNS) and in the Spanish society. In fact, the lack of recognition of genetic counsellors to support patients as well as the lack of knowledge about RD by the clinicians taking care of them [26] is translated into inappropriate genetic tests, lengthening the diagnostic process, increasing clinical expenses, and adding anxiety to patients.

4. Conclusions

The current situation of Genetic Counselling for RD in Spain is jeopardised by the lack of recognition of Clinical Genetics as a healthcare specialty within the SNS. This must include three professional profiles: clinical genetics, genetic counselling, and clinical laboratory genetics. Currently, there are more than 3 million people in Spain affected by a rare disease and the implementation of next generation sequencing technologies is improving diagnostic yield. However, it is necessary to create multidisciplinary teams (which include specialists providing Genetic Counselling) capable of analysing and interpreting this information, as well as providing information and support and accompanying families and patients with RD throughout this uncertain and unpredictable journey.

Furthermore, actualization of the current registries at the national level is needed to develop clinical guidelines and appropriate action strategies allowing better coordination between different centres to make society/professionals aware of the existence of CSURs and to create new ones capable of correctly managing patients regardless of their residence location.

Finally, updated and continuous training of health professionals on the new advances for diagnosis and treatment of RD will be necessary to guarantee equal access of patients to quality health services, thus improving the management of their disease and consequently, improving their quality of life.

References

  1. Macnamara, E.F.; Schoch, K.; Kelley, E.G.; Fieg, E.; Brokamp, E.; Signer, R.; LeBlanc, K.; McConkie-Rosell, A.; Palmer, C.G.S. Cases from the Undiagnosed Diseases Network: The continued value of counseling skills in a new genomic era. J. Genet. Couns. 2019, 28, 194–201.
  2. Ayres, S.; Gallacher, L.; Stark, Z.; Brett, G.R. Genetic counseling in pediatric acute care: Reflections on ultra-rapid genomic diagnoses in neonates. J. Genet. Couns. 2019, 28, 273–282. [Google Scholar] [CrossRef] [PubMed]
  3. Peron, A.; Au, K.S.; Northrup, H. Genetics, genomics, and genotype–phenotype correlations of TSC: Insights for clinical practice. Am. J. Med. Genet. Part C Semin. Med. Genet. 2018, 178, 281–290. [Google Scholar] [CrossRef] [PubMed]
  4. Bamshad, M.J.; Magoulas, P.L.; Dent, K.M. Genetic counselors on the frontline of precision health. Am. J. Med. Genet. Part C Semin. Med. Genet. 2018, 178, 5–9. [Google Scholar] [CrossRef]
  5. Merker, V.L.; Plotkin, S.R.; Charns, M.P.; Meterko, M.; Jordan, J.T.; Elwy, A.R. Effective provider-patient communication of a rare disease diagnosis: A qualitative study of people diagnosed with schwannomatosis. Patient Educ. Couns. 2021, 104, 808–814. [Google Scholar] [CrossRef]
  6. Merker, V.L.; Plotkin, S.R.; Charns, M.P.; Meterko, M.; Jordan, J.T.; Elwy, A.R. Effective provider-patient communication of a rare disease diagnosis: A qualitative study of people diagnosed with schwannomatosis. Patient Educ. Couns. 2021, 104, 808–814. [Google Scholar] [CrossRef]Helm, B.M. Exploring the Genetic Counselor’s Role in Facilitating Meaning-Making: Rare Disease Diagnoses. J. Genet. Couns. 2015, 24, 205–212. [Google Scholar] [CrossRef]
  7. Ormondroyd, E.; Mackley, M.P.; Blair, E.; Craft, J.; Knight, J.C.; Taylor, J.; Taylor, J.C.; Wilkie, A.O.M.; Watkins, H. Insights from early experience of a Rare Disease Genomic Medicine Multidisciplinary Team: A qualitative study. Eur. J. Hum. Genet. 2017, 25, 680–686. [Google Scholar] [CrossRef]
  8. Germain, D.P.; Moiseev, S.; Suárez-Obando, F.; Al Ismaili, F.; Al Khawaja, H.; Altarescu, G.; Barreto, F.C.; Haddoum, F.; Hadipour, F.; Maksimova, I.; et al. The benefits and challenges of family genetic testing in rare genetic diseases—Lessons from Fabry disease. Mol. Genet. Genom. Med. 2021, 9, e1666. [Google Scholar] [CrossRef] [PubMed]
  9. Cornel, M.C.; Rigter, T.; Jansen, M.E.; Henneman, L. Neonatal and carrier screening for rare diseases: How innovation challenges screening criteria worldwide. J. Community Genet. 2020, 12, 257–265. [Google Scholar] [CrossRef]
  10. Abulí, A.; Boada, M.; Rodríguez-Santiago, B.; Coroleu, B.; Veiga, A.; Armengol, L.; Barri, P.N.; Pérez-Jurado, L.A.; Estivill, X. NGS-Based Assay for the Identification of Individuals Carrying Recessive Genetic Mutations in Reproductive Medicine. Hum. Mutat. 2016, 37, 516–523. [Google Scholar] [CrossRef] [PubMed]
  11. Pollard, S.; Weymann, D.; Dunne, J.; Mayanloo, F.; Buckell, J.; Buchanan, J.; Wordsworth, S.; Friedman, J.M.; Stockler-Ipsiroglu, S.; Dragojlovic, N.; et al. Toward the diagnosis of rare childhood genetic diseases: What do parents value most? Eur. J. Hum. Genet. 2021, 29, 1491–1501. [Google Scholar] [CrossRef]
  12. Payne, K.; Eden, M. Measuring the economic value of genetic counselling. Eur. J. Med. Genet. 2019, 62, 385–389. [Google Scholar] [CrossRef] [PubMed]
  13. Willcocks, D.; Soulodre, C.; Zierler, A.; Cowan, K.; Smitko, E.; Schwarz, K.; Mcdowell, S.; Ng, V.; Mitchell, A.; Lang, A.; et al. Genome-Wide Sequencing for Unexplained Developmental Disabilities or Multiple Congenital Anomalies: A Health Technology Assessment. Ont. Health Technol. Assess. Ser. 2020, 20, 1–178. [Google Scholar]
  14. Raspa, M.; Moultrie, R.; Toth, D.; Haque, S.N. Barriers and Facilitators to Genetic Service Delivery Models: Scoping Review. Interact. J. Med. Res. 2021, 10, e23523. [Google Scholar] [CrossRef]
  15. Qian, E.; Thong, M.-K.; Flodman, P.; Gargus, J. A comparative study of patients’ perceptions of genetic and genomic medicine services in California and Malaysia. J. Community Genet. 2019, 10, 351–361. [Google Scholar] [CrossRef]
  16. BOE.es. BOE-A-2006-19626 Real Decreto 1302/2006, de 10 de Noviembre. Por el que se Establecen las BASES del procedimiento para la Designación y Acreditación de los Centros, Servicios y Unidades de Referencia del Sistema Nacional de Salud. 2006. Available online: https://www.boe.es/buscar/doc.php?id=BOE-A-2006-19626 (accessed on 5 December 2021).
  17. Martorell, L.; Cobo, A.M.; Baiget, M.; Naudó, M.; Poza, J.J.; Parra, J. Prenatal diagnosis in myotonic dystrophy type 1. Thirteen years of experience: Implications for reproductive counselling in DM1 families. Prenat. Diagn. 2007, 27, 68–72. [Google Scholar] [CrossRef]
  18. Yubero, D.; Benito, D.N.; Pijuan, J.; Armstrong, J.; Martorell, L.; Fernàndez, G.; Maynou, J.; Jou, C.; Roldan, M.; Ortez, C.; et al. The Increasing Impact of Translational Research in the Molecular Diagnostics of Neuromuscular Diseases. Int. J. Mol. Sci. 2021, 22, 4274. [Google Scholar] [CrossRef]
  19. Blanco-Kelly, F.; García Hoyos, M.; Lopez Martinez, M.; Lopez-Molina, M.; Riveiro-Alvarez, R.; Fernandez-San Jose, P.; Avila-Fernandez, A.; Corton, M.; Millan, J.; García Sandoval, B.; et al. Dominant Retinitis Pigmentosa, p.Gly56Arg Mutation in NR2E3: Phenotype in a Large Cohort of 24 Cases. PLoS ONE 2016, 11, e0149473. [Google Scholar] [CrossRef]
  20. Bravo-Gil, N.; Méndez-Vidal, C.; Romero-Pérez, L.; González-del Pozo, M.; Rodríguez-de la Rúa, E.; Dopazo, J.; Borrego, S.; Antiñolo, G. Improving the management of Inherited Retinal Dystrophies by targeted sequencing of a population-specific gene panel. Sci. Rep. 2016, 6, 23910. [Google Scholar] [CrossRef] [PubMed]
  21. van de Laar, I.; Arbustini, E.; Loeys, B.; Björck, E.; Murphy, L.; Groenink, M.; Kempers, M.; Timmermans, J.; Roos-Hesselink, J.; Benke, K.; et al. European reference network for rare vascular diseases (VASCERN) consensus statement for the screening and management of patients with pathogenic ACTA2 variants. Orphanet J. Rare Dis. 2019, 14, 264. [Google Scholar] [CrossRef]
  22. Ramalle-Gómara, E.; Domínguez-Garrido, E.; Gómez-Eguílaz, M.; Marzo-Sola, M.E.; Ramón-Trapero, J.L.; Gil-de-Gómez, J. Education and information needs for physicians about rare diseases in Spain. Orphanet J. Rare Dis. 2020, 15, 18. [Google Scholar] [CrossRef] [PubMed]
  23. Christian Hirsch, M.; Ronicke, S.; Krusche, M.; Doris Wagner, A. Rare diseases 2030: How augmented AI will support diagnosis and treatment of rare diseases in the future. Ann. Rheum. Dis. 2020, 79, 740–743. [Google Scholar] [CrossRef] [PubMed]
  24. Cordier, C.; McAllister, M.; Serra-Juhe, C.; Bengoa, J.; Pasalodos, S.; Bjornevoll, I.; Feroce, I.; Moldovan, R.; Paneque, M.; Lambert, D. The recognition of the profession of Genetic Counsellors in Europe. Eur. J. Hum. Genet. 2018, 26, 1719–1720. [Google Scholar] [CrossRef] [PubMed]
  25. Narayanan, D.; Udyawar, D.; Kaur, P.; Sharma, S.; Suresh, N.; Nampoothiri, S.; do Rosario, M.; Somashekar, P.; Rao, L.; Kausthubham, N.; et al. Multilocus disease-causing genomic variations for Mendelian disorders: Role of systematic phenotyping and implications on genetic counselling. Eur. J. Hum. Genet. 2021, 29, 1774–1780. [Google Scholar] [CrossRef]
  26. Zurynski, Y.; Deverell, M.; Dalkeith, T.; Johnson, S.; Christodoulou, J.; Leonard, H.; Elliott, E.J. Australian children living with rare diseases: Experiences of diagnosis and perceived consequences of diagnostic delays. Orphanet J. Rare Dis. 2017, 12, 68. [Google Scholar] [CrossRef]
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
Upload a video for this entry
Information
Subjects: Health Care Sciences & Services
Contributor MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register :
Sara Álvaro Sánchez
View Times: 360
Revisions: 4 times (View History)
Update Date: 24 Jan 2022
Table of Contents
    1000/1000
    Hot Most Recent
    Video Production Service
    Feedback